Xu-Dong Kong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xu-Dong Kong has a total of 186 co-authors. Here are the top co-authors by number of shared publications:
- Jian-He Xu
East China University of Science and Technology
14 shared publications Qi Chen
State Key Laboratory of Bioreactor Engineering Shanghai Collaborative Innovation Centre for Biomanufacturing East China University of Science and Technology Shanghai 200237 P.R. China
8 shared publications- Christian Heinis
Institute of Chemical Sciences and Engineering School of Basic Sciences École Polytechnique Fédérale de Lausanne (EPFL) Lausanne Switzerland
7 shared publications - Jiahai Zhou
Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China
7 shared publications Jian-He Xu
State Key Laboratory of Bioreactor Engineering, Shanghai Collaborative Innovation Center for Biomanufacturing, East China University of Science and Technology, Shanghai, China
7 shared publicationsBao-Di Ma
State Key Laboratory of Microbial Metabolism and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, China
5 shared publications
Latest Publications
- 12 September 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (38) , 12101-12105
Dihydrobenzofuran Formation through Ring Contraction of Dihydroisocoumarin Synthesized by a Polyketide Synthase Assembly Line with a Terminal Reductase Domain in Asperfuran Biosynthesis
Asperfuran is an antifungal natural product with a dihydrobenzofuran (DHB) nucleus. Herein, we identify a biosynthetic gene cluster responsible for its biosynthesis from Neosartorya pseudofischeri. Genetic and biochemical analysis revealed that the DHB nucleus of asperfuran is formed by a flavin-dependent monooxygenase-catalyzed ring contraction of a dihydroisocoumarin precursor, which is generated by a collaborative polyketide synthase assembly line with a C-terminal reductase domain. Our work unraveled a novel biosynthetic route to DHB synthesis.
- 12 September 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (38) , 12101-12105
Dihydrobenzofuran Formation through Ring Contraction of Dihydroisocoumarin Synthesized by a Polyketide Synthase Assembly Line with a Terminal Reductase Domain in Asperfuran Biosynthesis
Asperfuran is an antifungal natural product with a dihydrobenzofuran (DHB) nucleus. Herein, we identify a biosynthetic gene cluster responsible for its biosynthesis from Neosartorya pseudofischeri. Genetic and biochemical analysis revealed that the DHB nucleus of asperfuran is formed by a flavin-dependent monooxygenase-catalyzed ring contraction of a dihydroisocoumarin precursor, which is generated by a collaborative polyketide synthase assembly line with a C-terminal reductase domain. Our work unraveled a novel biosynthetic route to DHB synthesis.
- 3 August 2026
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 74 (31) , 24513-24522
Kinetic Resolution of Citronellol by an Engineered Alcohol Oxidase for the Production of ( R )-Citronellal and ( S )-Citronellol
(R)-citronellal is an important intermediate for aroma compounds and pharmaceuticals. Herein, we engineered the choline oxidase, AcCO6, from Arthrobacter chlorophenolicus, to enhance enantioselective oxidation of citronellol. Through site-directed and combinatorial mutagenesis, a quadruple mutant, AcCO6_M4a (W332V/A89S/W331F/N463E) was obtained, exhibiting 336% of the wild-type activity and a 10.2-fold improvement in enantioselectivity (E = 24.2). Structural analysis and MD simulations revealed that the mutations expanded the binding pocket, promoting favorable interactions with (R)-citronellol and enhancing hydride transfer, while disfavoring the (S)-enantiomer. Consequently, the catalytic efficiency (kcat/KM) for (R)-citronellol was 12.5-fold higher than that for (S)-citronellol. Kinetic resolution of racemic citronellol using AcCO6_M4a achieved approximately 50% conversion, yielding (R)-citronellal (86.7% ee) and (S)-citronellol (97.9% ee) with 39.1% and 42.0% yield, respectively. This work demonstrates the potential of engineered AcCO6 for enantioselective biocatalysis, offering an efficient route to synthesize chiral alcohols and aldehydes as intermediates for fragrances and pharmaceuticals.
- 3 August 2026
- Published by American Chemical Society (ACS) in Journal of Agricultural and Food Chemistry
- Vol. 74 (31) , 24513-24522
Kinetic Resolution of Citronellol by an Engineered Alcohol Oxidase for the Production of ( R )-Citronellal and ( S )-Citronellol
(R)-citronellal is an important intermediate for aroma compounds and pharmaceuticals. Herein, we engineered the choline oxidase, AcCO6, from Arthrobacter chlorophenolicus, to enhance enantioselective oxidation of citronellol. Through site-directed and combinatorial mutagenesis, a quadruple mutant, AcCO6_M4a (W332V/A89S/W331F/N463E) was obtained, exhibiting 336% of the wild-type activity and a 10.2-fold improvement in enantioselectivity (E = 24.2). Structural analysis and MD simulations revealed that the mutations expanded the binding pocket, promoting favorable interactions with (R)-citronellol and enhancing hydride transfer, while disfavoring the (S)-enantiomer. Consequently, the catalytic efficiency (kcat/KM) for (R)-citronellol was 12.5-fold higher than that for (S)-citronellol. Kinetic resolution of racemic citronellol using AcCO6_M4a achieved approximately 50% conversion, yielding (R)-citronellal (86.7% ee) and (S)-citronellol (97.9% ee) with 39.1% and 42.0% yield, respectively. This work demonstrates the potential of engineered AcCO6 for enantioselective biocatalysis, offering an efficient route to synthesize chiral alcohols and aldehydes as intermediates for fragrances and pharmaceuticals.
- Open Access
- 28 April 2026
- Published by Wiley in Advanced Energy and Sustainability Research
- Vol. 7 (5)
Engineering a Synthetic Formatotrophic Yeast With Enhanced Growth Capacity on Formate
Engineering Saccharomyces cerevisiae for growth on formate, a C1 feedstock derived from electrochemical activation of CO 2 , is a key solution to boost the development of formate‐mediated biomanufacturing and sustainable bioeconomy. Here, we developed a tripartite coupling strategy centered on serine that integrates formate assimilation and methanol dissimilation, enabling yeast growth on dual one‐carbon substrates. We first established a formate‐dependent yeast through constructing a serine‐autotrophic yeast and redesigning the reductive glycine (rGly) pathway, rendering the strain strictly dependent on formate for growth. Meanwhile, we identified mitochondrial and cytosolic serine deaminases (CHA1 mito and SDL1 cyto ) as the essential genes directing formate flux into central metabolism. Subsequently, we enhanced the supply of energy and reducing power by introducing methanol dissimilation pathways, which resulted in an optimal growth rate and improved formate utilization. Random mutagenesis screening yielded a strain with obligate growth on dual‐carbon substrates (formate as primary, methanol as auxiliary). Overall, our results demonstrate that establishing synthetic formatotrophy via rGly pathway requires efficient energy and reducing power, which facilitates the application of one‐carbon feedstocks in biorefineries.
- 28 April 2026
- Published by Wiley in Advanced Energy and Sustainability Research
- Vol. 7 (5)
Open AccessEngineering a Synthetic Formatotrophic Yeast With Enhanced Growth Capacity on Formate
Engineering Saccharomyces cerevisiae for growth on formate, a C1 feedstock derived from electrochemical activation of CO 2 , is a key solution to boost the development of formate‐mediated biomanufacturing and sustainable bioeconomy. Here, we developed a tripartite coupling strategy centered on serine that integrates formate assimilation and methanol dissimilation, enabling yeast growth on dual one‐carbon substrates. We first established a formate‐dependent yeast through constructing a serine‐autotrophic yeast and redesigning the reductive glycine (rGly) pathway, rendering the strain strictly dependent on formate for growth. Meanwhile, we identified mitochondrial and cytosolic serine deaminases (CHA1 mito and SDL1 cyto ) as the essential genes directing formate flux into central metabolism. Subsequently, we enhanced the supply of energy and reducing power by introducing methanol dissimilation pathways, which resulted in an optimal growth rate and improved formate utilization. Random mutagenesis screening yielded a strain with obligate growth on dual‐carbon substrates (formate as primary, methanol as auxiliary). Overall, our results demonstrate that establishing synthetic formatotrophy via rGly pathway requires efficient energy and reducing power, which facilitates the application of one‐carbon feedstocks in biorefineries.
- Open Access
A Divergent Class of Arylamine N-Acetyltransferases Catalyzes Convergent Amidative Condensation of Polyketides in Manumycins Biosynthesis
Polyketides are prized for their structural complexity and therapeutic potential, yet the incorporation of amide bonds into their frameworks typically relies on linear, nonribosomal peptide synthetase (NRPS)-dependent assembly. The direct, convergent coupling of distinct polyketide chains via amide bond formation—an ideal strategy for combinatorial biosynthesis—has remained largely elusive. Here, we report the discovery of a novel family of arylamine N-acetyltransferases (NATs) from manumycin-type biosynthetic pathways that catalyze an unprecedented intermolecular amidative chain transfer/condensation between an acyl carrier protein (ACP)-tethered polyketide donor and a free polyketide acceptor. Biochemical, structural, and molecular dynamics studies reveal that the representative enzyme, ColC2, possesses a distinctive substrate-binding pocket that diverges from canonical arylamine NATs, conferring exceptional promiscuity toward diverse acyl donors and acceptors. We demonstrate the utility of this biocatalyst by coupling arylamines with either synthetic acyl-thioesters or polyketide synthase (PKS) machinery to generate a library of non-natural polyketide amides and manumycin derivatives. These findings establish a new paradigm for amide bond formation in polyketide biosynthesis and position arylamine NATs as powerful tools for the development of novel therapeutics through combinatorial synthesis.
Open AccessA Divergent Class of Arylamine N-Acetyltransferases Catalyzes Convergent Amidative Condensation of Polyketides in Manumycins Biosynthesis
Polyketides are prized for their structural complexity and therapeutic potential, yet the incorporation of amide bonds into their frameworks typically relies on linear, nonribosomal peptide synthetase (NRPS)-dependent assembly. The direct, convergent coupling of distinct polyketide chains via amide bond formation—an ideal strategy for combinatorial biosynthesis—has remained largely elusive. Here, we report the discovery of a novel family of arylamine N-acetyltransferases (NATs) from manumycin-type biosynthetic pathways that catalyze an unprecedented intermolecular amidative chain transfer/condensation between an acyl carrier protein (ACP)-tethered polyketide donor and a free polyketide acceptor. Biochemical, structural, and molecular dynamics studies reveal that the representative enzyme, ColC2, possesses a distinctive substrate-binding pocket that diverges from canonical arylamine NATs, conferring exceptional promiscuity toward diverse acyl donors and acceptors. We demonstrate the utility of this biocatalyst by coupling arylamines with either synthetic acyl-thioesters or polyketide synthase (PKS) machinery to generate a library of non-natural polyketide amides and manumycin derivatives. These findings establish a new paradigm for amide bond formation in polyketide biosynthesis and position arylamine NATs as powerful tools for the development of novel therapeutics through combinatorial synthesis.
- Open Access
- 27 January 2026
- Published by Springer Nature in Bioresources and Bioprocessing
- Vol. 13 (1) , 14
Fed-batch strategies for the enhanced biotransformation of cis-epoxysuccinate to L-( +)-tartrate
L-( +)-Tartaric acid is a valuable organic acid with broad applications in the food, pharmaceutical, and chemical industries. Its eco-friendly synthesis typically relies on the enzymatic hydrolysis of cis -epoxysuccinate (CES) catalyzed by cis -epoxysuccinate hydrolases (CESHs), but conventional single-batch processes suffer from low space–time yields and poor continuity. To address these challenges, we devised two complementary fed-batch strategies to simplify the enzyme–product separation by exploiting differences in their solubilities. Strategy A employs carrier-free cross-linking immobilization of whole cells using 0.02% glutaraldehyde and 0.1% polyethylenimine. In this system, both the substrate sodium cis -epoxysuccinate (CESNa) and the product sodium L-( +)-tartrate remain soluble, while the enzyme is retained in the insoluble cell matrix. Under fed-batch operation, this configuration achieves a space–time yield of 150 g L −1 h −1 . Strategy B uses cell-free extract of CESH to hydrolyze calcium cis -epoxysuccinate (CESCa) with inherently low solubility. Here, the enzyme is fully soluble but the L-( +)-tartrate formed precipitates as an insoluble calcium salt, allowing easy separation of the product from the reaction mixture. This approach overcomes potential substrate inhibition and minimizes sodium-ion discharge, delivering a space–time yield of 136 g L −1 h −1 and a specific productivity of 484 g product /g catalyst . Both the soluble-product/insoluble-enzyme system (A) and the insoluble-product/soluble-enzyme system (B) represent effective strategies to streamline downstream processing and markedly enhance productivity. Together, they offer a viable route to scalable and cost-effective industrial production of L-( +)-tartaric acid. Graphical Abstract
- 27 January 2026
- Published by Springer Nature in Bioresources and Bioprocessing
- Vol. 13 (1) , 14
Open AccessFed-batch strategies for the enhanced biotransformation of cis-epoxysuccinate to L-( +)-tartrate
L-( +)-Tartaric acid is a valuable organic acid with broad applications in the food, pharmaceutical, and chemical industries. Its eco-friendly synthesis typically relies on the enzymatic hydrolysis of cis -epoxysuccinate (CES) catalyzed by cis -epoxysuccinate hydrolases (CESHs), but conventional single-batch processes suffer from low space–time yields and poor continuity. To address these challenges, we devised two complementary fed-batch strategies to simplify the enzyme–product separation by exploiting differences in their solubilities. Strategy A employs carrier-free cross-linking immobilization of whole cells using 0.02% glutaraldehyde and 0.1% polyethylenimine. In this system, both the substrate sodium cis -epoxysuccinate (CESNa) and the product sodium L-( +)-tartrate remain soluble, while the enzyme is retained in the insoluble cell matrix. Under fed-batch operation, this configuration achieves a space–time yield of 150 g L −1 h −1 . Strategy B uses cell-free extract of CESH to hydrolyze calcium cis -epoxysuccinate (CESCa) with inherently low solubility. Here, the enzyme is fully soluble but the L-( +)-tartrate formed precipitates as an insoluble calcium salt, allowing easy separation of the product from the reaction mixture. This approach overcomes potential substrate inhibition and minimizes sodium-ion discharge, delivering a space–time yield of 136 g L −1 h −1 and a specific productivity of 484 g product /g catalyst . Both the soluble-product/insoluble-enzyme system (A) and the insoluble-product/soluble-enzyme system (B) represent effective strategies to streamline downstream processing and markedly enhance productivity. Together, they offer a viable route to scalable and cost-effective industrial production of L-( +)-tartaric acid. Graphical Abstract
- 24 October 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (52)
Flipping of a Non‐productive Substrate Binding Conformation Facilitates Hydroxynitrile Lyase Catalyzed Hydrocyanation
Understanding enzyme–substrate conformational transformations is crucial to the design and engineering of biocatalysts. However, the mechanisms by which substrates undergo dynamic transformations that regulate the function of an enzyme remain poorly understood. Hydroxynitrile lyase from Prunus communis ( Pc HNL5) catalyzes the cleavage of cyanohydrins. Its reverse reaction holds significant synthetic potential for the preparation of pharmaceutical precursors. Using a combination of crystallography and computational experiments, a novel flipped substrate binding state is identified within the substrate tunnel of the Pc HNL5 L331A mutant. This binding state is non‐productive and undergoes a conformational change before the catalytic cycle can proceed. Site‐saturation mutagenesis led to the discovery of a triple mutant, Pc HNL5 L331A/S333V/P340L , that destabilizes the non‐productive substrate binding state thereby facilitating its transition to the catalytically productive conformation and significantly enhancing catalytic efficiency. Crystallographic studies provide a structural description of the factors that stabilize versus destabilize the different binding conformers in the different enzyme variants and thus the differing catalytic efficiencies. These findings demonstrate that destabilizing unfavorable substrate binding conformations within an enzyme active site can improve functionality and provide a promising strategy for designing efficient biocatalysts.
- 24 October 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (52)
Flipping of a Non‐productive Substrate Binding Conformation Facilitates Hydroxynitrile Lyase Catalyzed Hydrocyanation
Understanding enzyme–substrate conformational transformations is crucial to the design and engineering of biocatalysts. However, the mechanisms by which substrates undergo dynamic transformations that regulate the function of an enzyme remain poorly understood. Hydroxynitrile lyase from Prunus communis ( Pc HNL5) catalyzes the cleavage of cyanohydrins. Its reverse reaction holds significant synthetic potential for the preparation of pharmaceutical precursors. Using a combination of crystallography and computational experiments, a novel flipped substrate binding state is identified within the substrate tunnel of the Pc HNL5 L331A mutant. This binding state is non‐productive and undergoes a conformational change before the catalytic cycle can proceed. Site‐saturation mutagenesis led to the discovery of a triple mutant, Pc HNL5 L331A/S333V/P340L , that destabilizes the non‐productive substrate binding state thereby facilitating its transition to the catalytically productive conformation and significantly enhancing catalytic efficiency. Crystallographic studies provide a structural description of the factors that stabilize versus destabilize the different binding conformers in the different enzyme variants and thus the differing catalytic efficiencies. These findings demonstrate that destabilizing unfavorable substrate binding conformations within an enzyme active site can improve functionality and provide a promising strategy for designing efficient biocatalysts.
- 24 October 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (52) , e202515778
Flipping of a Non‐productive Substrate Binding Conformation Facilitates Hydroxynitrile Lyase Catalyzed Hydrocyanation
Understanding enzyme–substrate conformational transformations is crucial to the design and engineering of biocatalysts. However, the mechanisms by which substrates undergo dynamic transformations that regulate the function of an enzyme remain poorly understood. Hydroxynitrile lyase from Prunus communis ( Pc HNL5) catalyzes the cleavage of cyanohydrins. Its reverse reaction holds significant synthetic potential for the preparation of pharmaceutical precursors. Using a combination of crystallography and computational experiments, a novel flipped substrate binding state is identified within the substrate tunnel of the Pc HNL5 L331A mutant. This binding state is non‐productive and undergoes a conformational change before the catalytic cycle can proceed. Site‐saturation mutagenesis led to the discovery of a triple mutant, Pc HNL5 L331A/S333V/P340L , that destabilizes the non‐productive substrate binding state thereby facilitating its transition to the catalytically productive conformation and significantly enhancing catalytic efficiency. Crystallographic studies provide a structural description of the factors that stabilize versus destabilize the different binding conformers in the different enzyme variants and thus the differing catalytic efficiencies. These findings demonstrate that destabilizing unfavorable substrate binding conformations within an enzyme active site can improve functionality and provide a promising strategy for designing efficient biocatalysts.
- 24 October 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (52) , e202515778
Flipping of a Non‐productive Substrate Binding Conformation Facilitates Hydroxynitrile Lyase Catalyzed Hydrocyanation
Understanding enzyme–substrate conformational transformations is crucial to the design and engineering of biocatalysts. However, the mechanisms by which substrates undergo dynamic transformations that regulate the function of an enzyme remain poorly understood. Hydroxynitrile lyase from Prunus communis ( Pc HNL5) catalyzes the cleavage of cyanohydrins. Its reverse reaction holds significant synthetic potential for the preparation of pharmaceutical precursors. Using a combination of crystallography and computational experiments, a novel flipped substrate binding state is identified within the substrate tunnel of the Pc HNL5 L331A mutant. This binding state is non‐productive and undergoes a conformational change before the catalytic cycle can proceed. Site‐saturation mutagenesis led to the discovery of a triple mutant, Pc HNL5 L331A/S333V/P340L , that destabilizes the non‐productive substrate binding state thereby facilitating its transition to the catalytically productive conformation and significantly enhancing catalytic efficiency. Crystallographic studies provide a structural description of the factors that stabilize versus destabilize the different binding conformers in the different enzyme variants and thus the differing catalytic efficiencies. These findings demonstrate that destabilizing unfavorable substrate binding conformations within an enzyme active site can improve functionality and provide a promising strategy for designing efficient biocatalysts.
- Open Access
- 2 October 2025
- Published by Springer Nature in Cellular Oncology
- Vol. 48 (6) , 1757-1774
Development of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects
Purpose Despite advancements in 177Lu-based radiotherapy for cancer, its efficacy against refractory cold tumors remains limited. Targeted peptide-radionuclide conjugates (PRCs) combined with immunotherapy are emerging as promising theranostic strategies to maximize anti-tumor effectiveness. Methods Cyclic peptide CEMJ4 was identified via phage selection, and further conjugated with DOTA and radiolabeled with 68Ga for diagnostic imaging and 177Lu for cancer therapy. The druggability was assessed by in vitro cell experiments, in vivo PET/CT imaging and biodistribution. Additionally, the feasibility of combining 177Lu-DOTA-CEMJ4 with a hematopoietic progenitor kinase 1 inhibitor (HPK1i) was evaluated in B16F10 tumor-bearing mice, focusing on the anti-tumor immune response and tumor growth. Results CEMJ4 exhibited high affinity for human erythropoietin-producing hepatocellular receptor A2 (EphA2; KD = 0.3 ± 0.2 µM), a therapeutic target overexpressed in several solid tumors. Radiolabeled 68Ga/177Lu-DOTA-CEMJ4 specifically bound to EphA2-expressing B16F10 cells and tumor models, effectively inhibiting tumor growth. Notably, 177Lu-induced T cell immunotoxicity was reversed by HPK1i, which modulated T cell dysfunction. Combining 177Lu-DOTA-CEMJ4 with HPK1i significantly reduced tumor burden and increased tumor-infiltrating CD4+ T cells, CD8+ T cells, and M1 macrophages. Conclusion This study identifies CEMJ4 as a promising peptide ligand for tumor-targeted radionuclide delivery and emphasizes the clinical potential of radionuclide therapy combined with immunotherapy in theranostics to enhance therapeutic precision and efficacy. Graphical Abstract
- 2 October 2025
- Published by Springer Nature in Cellular Oncology
- Vol. 48 (6) , 1757-1774
Open AccessDevelopment of a 177Lu-labeled EphA2-targeting cyclic peptide combined with an HPK1 inhibitor for synergistic anti-tumor effects
Purpose Despite advancements in 177Lu-based radiotherapy for cancer, its efficacy against refractory cold tumors remains limited. Targeted peptide-radionuclide conjugates (PRCs) combined with immunotherapy are emerging as promising theranostic strategies to maximize anti-tumor effectiveness. Methods Cyclic peptide CEMJ4 was identified via phage selection, and further conjugated with DOTA and radiolabeled with 68Ga for diagnostic imaging and 177Lu for cancer therapy. The druggability was assessed by in vitro cell experiments, in vivo PET/CT imaging and biodistribution. Additionally, the feasibility of combining 177Lu-DOTA-CEMJ4 with a hematopoietic progenitor kinase 1 inhibitor (HPK1i) was evaluated in B16F10 tumor-bearing mice, focusing on the anti-tumor immune response and tumor growth. Results CEMJ4 exhibited high affinity for human erythropoietin-producing hepatocellular receptor A2 (EphA2; KD = 0.3 ± 0.2 µM), a therapeutic target overexpressed in several solid tumors. Radiolabeled 68Ga/177Lu-DOTA-CEMJ4 specifically bound to EphA2-expressing B16F10 cells and tumor models, effectively inhibiting tumor growth. Notably, 177Lu-induced T cell immunotoxicity was reversed by HPK1i, which modulated T cell dysfunction. Combining 177Lu-DOTA-CEMJ4 with HPK1i significantly reduced tumor burden and increased tumor-infiltrating CD4+ T cells, CD8+ T cells, and M1 macrophages. Conclusion This study identifies CEMJ4 as a promising peptide ligand for tumor-targeted radionuclide delivery and emphasizes the clinical potential of radionuclide therapy combined with immunotherapy in theranostics to enhance therapeutic precision and efficacy. Graphical Abstract
- 18 August 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
Phage Selection of Cyclic Peptides Inhibiting Aminoglycoside Phosphotransferases to Control Resistant Bacteria
The clinical threat of aminoglycoside phosphotransferases (APHs) stems from their efficient inactivation of aminoglycosides, driving multidrug resistance through broad-spectrum antibiotic modification. While peptide-based inhibitors represent a promising therapeutic modality, current candidates lack sufficient potency against APHs. To address this limitation, we employed phage display technology to screen large cyclic peptide libraries (structural diversity >1011) against APH(3')-Ia, a clinically relevant enzyme derived from Escherichia coli. Our selection identified cyclic peptide families exhibiting nanomolar binding affinities characterized by two conserved motifs: CXW(P/L)LC and CP(W/F)YC. Intriguingly, divalent cations (Mg2+ and Ca2+) enhanced peptide-APH interactions, suggesting a metal-dependent binding mechanism. Competitive fluorescence polarization assays revealed that these cyclic peptides primarily occupy the ATP-binding pocket of APH(3')-Ia, with representative candidate A-L3 demonstrating significant enzymatic inhibition. This study establishes a foundation for developing APH-targeted antibiotic adjuvants through (1) identification of novel cyclic peptide scaffolds with inhibitory potential, (2) elucidation of divalent metal ion effects on inhibitor binding, and (3) mechanistic insights into ATP-binding site competition. These findings provide critical structural and functional information to guide the rational design of next-generation antibiotic resistance breakers.
- 18 August 2025
- Published by American Chemical Society (ACS) in ACS Chemical Biology
Phage Selection of Cyclic Peptides Inhibiting Aminoglycoside Phosphotransferases to Control Resistant Bacteria
The clinical threat of aminoglycoside phosphotransferases (APHs) stems from their efficient inactivation of aminoglycosides, driving multidrug resistance through broad-spectrum antibiotic modification. While peptide-based inhibitors represent a promising therapeutic modality, current candidates lack sufficient potency against APHs. To address this limitation, we employed phage display technology to screen large cyclic peptide libraries (structural diversity >1011) against APH(3')-Ia, a clinically relevant enzyme derived from Escherichia coli. Our selection identified cyclic peptide families exhibiting nanomolar binding affinities characterized by two conserved motifs: CXW(P/L)LC and CP(W/F)YC. Intriguingly, divalent cations (Mg2+ and Ca2+) enhanced peptide-APH interactions, suggesting a metal-dependent binding mechanism. Competitive fluorescence polarization assays revealed that these cyclic peptides primarily occupy the ATP-binding pocket of APH(3')-Ia, with representative candidate A-L3 demonstrating significant enzymatic inhibition. This study establishes a foundation for developing APH-targeted antibiotic adjuvants through (1) identification of novel cyclic peptide scaffolds with inhibitory potential, (2) elucidation of divalent metal ion effects on inhibitor binding, and (3) mechanistic insights into ATP-binding site competition. These findings provide critical structural and functional information to guide the rational design of next-generation antibiotic resistance breakers.
- Open Access
- 15 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (9) , 110599
ADP-ribose is a competitive inhibitor of methanol dehydrogenases from Bacillus methanolicus
- 15 August 2025
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 301 (9) , 110599
Open AccessADP-ribose is a competitive inhibitor of methanol dehydrogenases from Bacillus methanolicus